Life sciences consulting: Literature

Competitors in China’s life sciences market should prepare themselves for the market’s massive changes and continued growth by increasing their capabilities in three key areas: innovation; manufacturing quality; and sales, marketing and distribution.

Service-oriented architecture (SOA) can serve as the new blueprint for aligning business and IT.

Within an industry in need of the type of collaboration that gave rise to the biotech era, new models are emerging that can facilitate partnership between life sciences companies and academic institutions, diminish the sting of past failures and result in significant therapeutic advances.

Fewer than half the respondents in the latest biopartnering survey jointly conducted by the IBM Institute for Business Value and Silico Research say that their alliances have met their expectations

Imaging biomarkers hold great promise to assuage some of society’s costliest challenges, and technology can accelerate progress as the full ecosystem - including government, academia, BioPharma industry and imaging industry - contributes toward achieving this vision.

The science of biomarker-enabled R&D is advancing quicker than general acceptance. To realize the full potential of biomarkers, the industry must take actions to increase the confidence of regulators, the medical community and the public at large.

Partnerships are vital to large biopharmaceutical companies - and yet many lack the collaborative capabilities they need. This study outlines the characteristics biotechs and academics are looking for in a partner and suggests ways larger companies can become more attractive suitors.

CEOs across the Life Sciences industry weigh in on the future of business.

To make serious strides toward improving patient health, the pharmaceutical and healthcare industries need to marshall their collective data assets and collaborate more closely.

The pharmaceutical industry (Pharma) is at a critical point in its transition to a new model of drug development: making targeted medicines.

Pharma must increase the number of trials it conducts and reduce the amount of time those trials take. Electronic data capture (EDC) can help Pharma work more smartly with the finite resources it commands.

Recent advances in molecular science are expected to yield medical treatments targeted not just for individual ailments, but also for highly segmented patient groups. As they pursue this exciting vision, pharmaceutical and biotechnology (biotech) companies are actively engaging in alliances.

If the pharmaceutical industry adopts a new business model based on "targeted treatment solutions," it will be able to achieve breakthrough growth. These integrated solutions will be used to benefit patients, payers, physicians and the industry itself.

IBM Business Consulting Services conducted the 2004 IBM European supply chain survey with L'Usine Nouvelle magazine. This survey identifies current practices, significant trends and operational performance benchmarks in five key areas of supply chain management (SCM).

This paper identifies the seven key technologies that IBM believes will drive innovation in the life sciences over the next decade. All seven technologies once belonged in the realm of science fiction, but they are fast becoming fact.

This survey identifies current practices, captures significant trends and establishes operational performance benchmarks in five key areas of supply chain management (SCM): new product development, supply chain planning, customer order management, procurement and logistics.

Few would disagree that the pharmaceutical industry is facing major challenges. Our business on demand view offers approaches for improving the bottom line and addressing the challenges the industry faces.

This paper explores the opportunities for automating the pharmaceutical R&D process, with the introduction of in silico technologies, e-business operations and new Web-based search portals.

At one time, the pharmaceutical supply chain was featured on the boardroom agenda only when things went wrong. Today, it is subject to much greater scrutiny, as companies everywhere focus on how best to launch new drugs, assure the safety and supply of those drugs and simultaneously cut costs.

Pharma's new world view: Transforming R&D through emerging markets